Find your next paid study

~$10 – $6,250

Mayo ClinicNCT05110144

Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more

MC220806: Phase I Study Evaluating the Efficacy of CSF1R and TAM Receptor or Inhibition in Hematologic Malignancies With Q702, a Small Molecular Inhibitor

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications …

Outcomes of Patients With Thyroid Carcinoma Treated With Redifferentiating Agents as Part of Routine Clinical Care: A Prospective Data Collection Study

The purpose of this study to learn more about the use of redifferentiating medications as a standard treatment for radioactive iodine/RAI-refractory thyroid ca…

Thyroid CancerThyroidRefractory Thyroid Cancer

Memorial Sloan Kettering Cancer CenterNCT05733013

~$10 – $750

Relapsed/Refractory B-cell Malignancies

A Phase Ia/Ib, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic of UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with rela…

Ubix Therapeutics, Inc.NCT06590961

Phase 2

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer…

Platinum-resistant Ovarian CancerRefractory Ovarian Carcinoma

Cybrexa TherapeuticsNCT06315491

Recurrent Acute Myeloid LeukemiaRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more

A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation

This phase I/II trial studies the side effects and best dose of gilteritinib and to see how well it works in combination with azacitidine and venetoclax in tre…

M.D. Anderson Cancer CenterNCT04140487

~$10 – $6,250

Observational

Early Versus Late Endoscopic Temporary Stenting for Management of Refractory Benign Esophageal Strictures

This project is being done to compare two current treatment clinical options for management of RBES: 1) Frequent dilations followed by temporary esophageal ste…

Refractory Benign Esophageal Strictures

Medical College of WisconsinNCT06991049

~$10 – $6,250

LeukemiaLeukemia, MyeloidLeukemia, Myeloid, Acute+3 more

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myeloge…

BlossomHill TherapeuticsNCT06501196

Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory

A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to determine if UF-KURE-BCMA (B-Cell Maturation Antigen) chimeric antigen receptor T cells (CAR-T cells) can be used to treat rela…

~$10 – $7,500

David WaldNCT06698744

Recurrent Adult T-Cell Leukemia/LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Adult T-Cell Leukemia/Lymphoma+1 more

A Pilot Phase I Trial of IL-21 Expanded, Off the Shelf, Third-Party Natural Killer (NK) Cells in Combination With Mogamulizumab in Patients With Cutaneous T-Cell Lymphomas or Adult T-Cell Leukemia/Lymphomas

This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in…

Refractory Ventricular Tachycardia

~$10 – $7,500

John ReneauNCT04848064

Observational

Saline Enhanced Radiofrequency (SERF) Needle Ablation for Refractory VT

The Thermedical Ablation System and Durablate catheter is indicated for use in patients with recurrent, sustained, monomorphic ventricular tachycardia (SMVT) r…

Thermedical, Inc.NCT05337241

B-Cell Non-Hodgkin Lymphoma-RecurrentDiffuse Large B-Cell Lymphoma-RecurrentFollicular Lymphoma-Recurrent+9 more

Early, Risk Adapted CC-99282 + Rituximab Post CAR T-Cell Therapy for Non-Hodgkin's Lymphoma

This phase I trial tests the safety, side effects and best dose of CC-99282 with rituximab for the treatment of patients who have received chimeric antigen rec…